Breaking News, Financial News

Catalent 3rd Quarter Results

Revenues down 19% to $1.04 billion, while costs associated with Consumer Health unit contribute to loss of $227 million in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent 3Q Revenues: $1.04 billion (-19%) 3Q Loss: $227 million (earnings were $141 million 3Q22) Comments: Biologics revenue was $475 million in the quarter, down 32%. Pharma and Consumer Health revenues were $563 million, down 2%. Loss in the quarter includes a goodwill impairment of $210 million associated with the company’s Consumer Health reporting unit. Unallocated costs in the quarter were $256 million, compared to $54 million in 3Q22. Restructuring costs in the quarter and Dece...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters